STOCK TITAN
  1. Home
  2. News
  3. BMY

Bristol Myers Squibb Announces Dividend

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
dividends
Rhea-AI Summary
Bristol Myers Squibb (BMY) declares quarterly dividends for common and preferred stockholders, with $0.60 per share for common stock and $0.50 per share for convertible preferred stock.
Positive
  • None.
Negative
  • None.

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents ($0.60) per share on the $0.10 par value common stock of the company. The dividend is payable on May 1, 2024, to stockholders of record at the close of business on April 5, 2024.

In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company’s $2.00 convertible preferred stock, payable on June 3, 2024, to stockholders of record at the close of business on May 7, 2024.

About Bristol Myers Squibb Company
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

corporatefinancial-news

Media:

media@bms.com

Investors:

investor.relations@bms.com

Source: Bristol Myers Squibb

Bristol Myers Squibb has declared a quarterly dividend of $0.60 per share for its common stock.

The dividend for Bristol Myers Squibb's common stock will be payable on May 1, 2024.

Bristol Myers Squibb has declared a quarterly dividend of $0.50 per share for its convertible preferred stock.

The dividend for Bristol Myers Squibb's convertible preferred stock will be payable on June 3, 2024.
Stock BMY logo
Bristol-Myers Squibb Co.

NYSE:BMY

BMY Rankings

#130 Ranked by Market Cap
#4058 Ranked by Stock Gains
#580 Ranked by Dividends

BMY Latest News

Apr 26, 2024
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
Apr 25, 2024
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
Apr 22, 2024
Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster
Apr 11, 2024
Building a Better Future: Bristol Myers Squibb 2023 ESG Report
Apr 8, 2024
KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

BMY Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Pharmaceuticals: Major, Manufacturing, Pharmaceutical Preparation Manufacturing
US
New York

About BMY

The Bristol-Myers Squibb Company is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the worlds largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.